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S U M M A R Y
Background: Group B Streptococcus (GBS) is a known causative pathogen of neonatal sepsis, but the
epidemiology in non-pregnant adults is less studied.
Methods: Retrospective case–control and cohort analyses of risk factors and outcomes of GBS infections
among non-pregnant adults were conducted at the Detroit Medical Center from January 2005 to May
2010. Uninfected controls were matched to cases in a 3:1 ratio. Data were obtained from charts and
pharmacy records. Identiﬁcation of the bacteria and antimicrobial susceptibility testing were
determined by MicroScan. Cox regression was used for matched multivariate analyses.
Results: Thirty-two patients with GBS infections were identiﬁed and were matched and compared to 96
controls. Compared to controls, patients with GBS infection were signiﬁcantly younger. Immunosup-
pression, attributable mainly to neutropenia and recent use of glucocorticoids, was an independent
predictor for GBS infection (odds ratio 2.7, p = 0.03). Nine (28%) of the patients with GBS infection had
bacteriological failure despite the administration of appropriate antimicrobial therapy. Of the 10
patients with bloodstream infections (BSI), three had endocarditis and four had central nervous system
(CNS) infections. During the study period the incidence of infections decreased, but the rates of
resistance to erythromycin and clindamycin increased.
Conclusions: GBS, previously considered a genitourinary pathogen, has emerged as a non-nosocomial
opportunistic pathogen causing BSI, endocarditis, and CNS infections. Immunosuppression, particularly
transient immunosuppressed states, was an independent predictor for GBS BSI. Resistance rates to
macrolides and clindamycin continue to increase, and should be closely monitored.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Group B Streptococcus (GBS), Streptococcus agalactiae, is a Gram-
positive coccus that can cause serious early invasive disease in
newborns.1 A successful global intervention involving the adminis-
tration of intrapartum chemoprophylaxis to maternal populations at
risk, has signiﬁcantly decreased the rate of this devastating
condition.2 However, GBS can also cause infections in pregnant
and non-pregnant adults, with estimated annual incidence ranging
from 4 to 7 cases per 100 000 patients and a case-fatality rate over
30%, though recent data point to lower case-fatality rates.1,3–5 The
extensive research efforts conducted on GBS neonatal disease have
facilitated the exploration of microbiological characteristics of the
pathogen and have enhanced the development of diagnostic,
treatment, and prevention modalities that are applicable to the
management of GBS infections in adults as well.3,6–8* Corresponding author. Tel.: +1 313 745 1714; fax: +1 313 993 0302.
E-mail address: drormc@hotmail.com (D. Marchaim).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.11.008In order to apply appropriate preventive measures and
interventions, the population at risk needs to be meticulously
deﬁned. Several epidemiological analyses pertaining to risk factors
for GBS infections among non-pregnant adults have been
published.3–5,9–16 Most of the risk factors reported were based
on case series, without use of control groups.3,4,9,17 A later study
enrolled controls,12 but did not match for the ‘time at risk’, which
according to methodological papers subsequently published,
represents the most important parameter to control for when
studying risk factors for hospital infections, to ensure that controls
truly represent the background population from which cases
arose.18–20 In addition, the study did not apply systemic
inﬂammatory response syndrome (SIRS)-based deﬁnitions21 in
order to differentiate infected patients from patients colonized
only but not infected with GBS.12
The aim of this study was to design a case–control and cohort
investigation of risk factors and outcomes, respectively, associated
with GBS infections among non-pregnant adults, using appropriate
methodology to match controls to cases and differentiate patients
with GBS infection from those only colonized.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Study setting and design
A retrospective case–control and cohort study was initiated at
the Detroit Medical Center (DMC) healthcare system, which
consists of eight hospitals, has more than 2200 inpatient beds,
and serves as a tertiary referral facility for Metropolitan Detroit
and Southeastern Michigan. DMC has a single centralized
clinical microbiology laboratory, which processes approximately
500 000 samples annually. Multiple outpatient facilities in
Southeast Michigan use DMC’s laboratory services on a routine
basis. Patients with GBS isolated from January 1, 2005 to 30 April,
2010 were matched and compared in a 1:3 ratio to a group of
‘uninfected controls’, i.e., patients who did not have GBS isolation
during their hospital or outpatient facility stay. Matching
parameters included: (1) hospital or outpatient facility, (2) unit
or clinic, (3) calendar year, and (4) time at risk, i.e., time from
admission to culture. For uninfected hospitalized controls, in
order to match for time at risk, the total length of hospital stay
had to be at least as long as the time at risk of the matched case.
For GBS isolated in the emergency room or outpatient settings,
uninfected controls were selected if they visited the same
location, were not hospitalized, and did not have isolation of GBS.
Eligible controls were randomly selected using the randomiza-
tion function in Excel (Microsoft). Institutional review boards at
Wayne State University and DMC approved the study prior to its
initiation.
2.2. Patients and clinical variables
GBS cases consisted of all adult (18 years) non-pregnant
patients who had a GBS-positive clinical culture, sent from all
inpatient and outpatient facilities that submit specimens to the
DMC laboratory, coupled with clinical signs of infection; isolates
representing only a colonization state were excluded.21 Cultures
from all anatomic sites were evaluated. For patients who had more
than one GBS culture positive during the study period, only the ﬁrst
episode of GBS infection was analyzed (i.e., unique patient
episodes).
Parameters retrieved from patient charts included: (1)
demographics; (2) background conditions and comorbidities
prior to infection (or admission for uninfected controls),
including Charlson scores,22 and immunosuppressive condi-
tions; (3) recent healthcare-associated exposures including
invasive procedures; (4) exposures to antimicrobials in the past
3 months; and (5) patient outcomes including: in-hospital and
90-day mortality, length of hospital stay, functional status
deterioration (deﬁned as deterioration from admission to
discharge in 1 activities of daily living according to the Katz
criteria),23 invasive procedures in the following 3 months, and
discharge to a long-term care facility (LTCF) after being admitted
from home. For GBS cases only, additional parameters that were
retrieved from charts and pharmacy records included: (1)
severity of acute illness indices including McCabe score24 and
severity of sepsis levels;21 (2) ‘bacteriological failure’, i.e.,
additional GBS isolation in the 3 months following the index
culture; and (3) factors related to antimicrobial therapy
including: empiric therapy (deﬁned as therapy administered
from 48 h before to 72 h following the date that the GBS culture
was obtained), the main ‘consolidative’ antimicrobial regimen
(i.e., antibiotics provided at >72 h following GBS isolation and up
to 14 days following isolation), and the time to initiation of
effective therapy in hours. Effective therapy was deﬁned as
therapy with an antimicrobial agent that demonstrated in vitro
activity against the GBS isolate.2.3. Microbiology
Bacteria were identiﬁed to the species level, and susceptibilities
were determined to pre-deﬁned antimicrobials, based on an
automated broth microdilution system (MicroScan; Siemens AG,
Germany), and in accordance with Clinical and Laboratory
Standard Institute (CLSI) criteria and breakpoints.25
2.4. Statistical analysis
All analyses were performed using SPSS v.19 (2011; IBM–SPSS,
Chicago, IL, USA). Bivariate matched analyses were performed
using the Fisher’s exact test or the Chi-square test for categorical
variables and the dependent samples t-test or Wilcoxon rank sum
test for continuous variables. A matched multivariable model for
GBS risk factors was constructed using Cox regression. All variables
with a p-value of <0.1 in the bivariate analyses were considered for
inclusion in the multivariate model. A stepwise selection proce-
dure was used to select variables for inclusion in the ﬁnal model.
All p-values were two-sided. In addition to examining statistical
signiﬁcance and confounding, effect modiﬁcation between vari-
ables was evaluated by testing appropriate interaction terms for
statistical signiﬁcance. When effect modiﬁcation was detected,
subgroup analyses were performed.
3. Results
During the 112-month study period there were 32 unique
patient cases of GBS infection that met the inclusion criteria. Only
two were isolated 72 h into the hospitalization. Cases were
matched to 96 controls. None of the GBS isolates were resistant to
penicillin (median minimum inhibitory concentration (MIC) 0.06,
interquartile range (IQR) 0.06–0.12) or ceftriaxone (median MIC
0.13, IQR 0.06–0.13); ﬁve (19%) were resistant to clindamycin
(median MIC 0.03, IQR 0.03–0.12) and nine (33%) to erythromycin
(median MIC 0.03, IQR 0.02–0.25). Three (10.7%) of the isolates
were resistant to vancomycin per the automated system (median
MIC 0.5, IQR 0.5–0.5). However, unfortunately these strains from
2006–2007 were not saved, nor validated in other tests or
conﬁrmed in other laboratories. Ten GBS isolates were from the
blood (31%), eight from urine (25%), 13 from wounds (41%), and
one (3%) from cerebrospinal ﬂuid (CSF). Three (10%) of the cases
were diagnosed with deﬁnite endocarditis and four (13%) of the
cases had a central nervous system (CNS) infection (three of whom
were bacteremic). During the acute GBS illness, six (19%) of the
patients were transferred to an intensive care unit (ICU), ﬁve (16%)
required acute mechanical ventilation, 12 (38%) had a central
venous catheter inserted, and 11 (34%) developed acute renal
insufﬁciency.
3.1. GBS risk factors and outcomes
The bivariate analysis of cases versus controls is displayed in
Table 1. Overall, control patients were older, more frequently had a
recent stay in ICU, and had a higher index of comorbidities. Patients
with GBS infection were prone to have an allergy to b-lactam
antibiotics compared to controls (10 (31.3%) vs. 15 (15.6%), odds
ratio (OR) 1.9, 95% conﬁdence interval (95% CI) 1.02–3.4; p = 0.05).
Immunosuppression was more common among patients with GBS
infection. Immunosuppression was mainly attributed to tempo-
rary states like neutropenia and recent glucocorticoid use, and not
to more permanent states such as a malignant comorbidity or
AIDS. The group of patients with GBS and immunosuppression
were particularly prone to suffer from severe acute illness indices
(i.e. three were transferred to the ICU, three were acutely
intubated, ﬁve underwent an acute invasive procedure, and six
Table 1
Bivariate analysis of patients infected with group B Streptococcus versus matched controls, Detroit Medical Center, 2005–2010
Parametera Cases (n = 32) Controls (n = 96) OR 95% CI p-Value
Demographics
Age, years 48.2  14.3 57.5  18.4 0.01
Elderly (>65 years) 3 (9.4%) 33 (34.4%) 0.2 0.06–0.7 0.006
Female gender 21 (65.6%) 51 (53.1%) 0.59 0.26–1.36 0.30
African American 24 (75%) 72 (75%) 1 0.4–2.8 1
Residence in LTCF 2 (6.3%) 12 (12.5%) 0.47 0.09–2.2 0.52
Acute and chronic conditions on admission
Dependent functional status 11 (34.4%) 37 (38.5%) 0.83 0.36–1.9 0.83
Reduced conscious level 3 (9.4%) 24 (25%) 0.31 0.09–1.1 0.08
McCabe score 2.8  0.42 2.7  0.6 0.44
Rapidly fatal condition per McCabe score 0 8 (8.3%) 0.2
Malignancy 8 (25%) 19 (19.8%) 1.35 0.53–3.5 0.62
Diabetes 14 (43.8%) 32 (33.3%) 1.56 0.69–3.5 0.29
Chronic liver disease 2 (6.3%) 6 (6.3%) 1 0.19–5.2 1
HIV infection 0 1 (1.0%) 1
Chemotherapy in past 3 months 3 (9.4%) 7 (7.3%) 1.3 0.3–5.4 0.7
Radiotherapy in past 3 months 2 (6.3%) 3 (3.1%) 2.1 0.3–13 0.6
Neutropenia 4 (12.5%) 2 (2.1%) 6.7 1.17–38.6 0.034
Glucocorticoid consumption in the past month 10 (31.3%) 10 (10.4%) 3.9 1.45–10.6 0.01
Transplantation in the past 1 (3.1%) 5 (5.2%) 0.6 0.07–5.2 1
Anti-TNF-a therapy in past 3 months 1 (3.1%) 2 (2.1%) 1.5 0.1–17.3 1
Immunosuppressive states overallb 14 (43.8%) 21 (21.9%) 2.8 1.1–7.1 0.02
Charlson combined condition score 4.5 (1.3–7.8) 7.5 (3–10) 0.11
Charlson 10-year survival probability, % 37 (0–93.8) 7.5 (0–77) 0.15
Exposure to healthcare settings and environments before GBS isolation
Hospitalized in past 3 months 11 (34.4%) 43 (44.8%) 0.65 0.281.49 0.41
ICU stay in past 3 months 2 (6.3%) 31 (32.3%) 0.14 0.03–0.62 0.002
Hemodialysis 1 (3.1%) 8 (8.3%) 0.36 0.04–2.9 0.45
Invasive procedures in past 6 monthsc 16 (50%) 44 (45.8%) 1.18 0.53–2.6 0.69
Permanent devicesd 17 (53.1%) 59 (61.5%) 0.71 0.32–1.6 0.42
Antimicrobial therapy in past 3 months
Any antibiotics 8 (25.8%) 24 (25%) 1.04 0.41–2.64 1
Time from last antibiotic, days 17  19 17  27 0.99
No. of antibiotics in preceding 3 months 0 (0–2) 0 (0–0.8) 0.22
Clindamycin in the preceding 3 months 4 (12.5%) 1 (1.0%) 13.6 1.5–126.4 0.014
Outcomes
In-hospital mortality 1 (3.1%) 8 (8.3%) 0.36 0.04–2.95 0.45
3-month mortality 2 (6.3%) 11 (11.5%) 0.52 0.11–2.46 0.52
Functional status deterioration following hospitalization 5 (15.6%) 20 (20.8%) 0.7 0.24–2.1 0.61
Discharged to LTCF after being admitted from homee 2 (6.5%) 7 (8.2%) 0.77 0.15–3.9 1
Additional hospitalizations in 6 monthse 17 (53.1%) 42 (43.8%) 1.46 0.65–3.3 0.42
Invasive procedures in 3 monthsc 13 (40.6%) 24 (25%) 2.1 0.88–4.8 0.12
Length of hospital stay, days 5.5 (3.3–13.8) 7 (4–13.8) 0.58
OR, odds ratio; 95% CI, 95% conﬁdence interval; LTCF, long-term care facility; HIV, human immunodeﬁciency virus; TNF-a, tumor necrosis factor alpha; GBS, group B
Streptococcus; ICU, intensive care unit.
a Results are n (%), mean  standard deviation, or median (interquartile range).
b Disease states included: HIV, neutropenia, glucocorticoid use in past month, chemotherapy in past 3 months, radiotherapy in past 3 months, post-transplantation, and
anti-TNF therapy in past 3 months.
c Include: any type of surgery, biopsy, percutaneous intervention, or endoscopy.
d Include: central venous tunneled catheter, permanent urinary catheter, gastrostomy, tracheotomy, and orthopedic external ﬁxator.
e Percents are expressed as ‘‘valid percents’’, i.e. excluding the missing.
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endocarditis and two of four cases with CNS infection had an
immunosuppressive state.
A multivariate matched model for predictors of GBS disease was
conducted. After controlling for age and recent stay in the ICU,
immunosuppression remained an independent signiﬁcant predic-
tor for GBS infection (OR 2.7, 95% CI 1.1–6.5; p = 0.03).
Most of the outcomes of patients with GBS disease were
favorable compared to the outcomes of controls. However
readmission to the hospital in the following 6 months and invasive
procedures conducted in the 3 months following the index
hospitalization occurred more commonly among cases with GBS
infection. Two patients with GBS died within 3 months of
infection; one due to a CNS infection and the other due to
endocarditis. Nine (28%) of the case patients were deﬁned as
bacteriological failures despite receiving effective empiric and
consolidative antimicrobial regimens, with a median time to
effective therapy of zero hours (IQR 0–39).3.2. GBS trends analyses
From 2005 to 2010, the prevalence and incidence of GBS
isolations at DMC decreased (from an incidence of 0.04 to 0.01 per
1000 patients-days; p-value for trend = 0.09) (Figure 1). However,
during the same period, the resistance rates to both erythromycin
(p-value for trend = 0.16) and clindamycin (p-value for
trend = 0.06) increased.
4. Discussion
The epidemiology of GBS infections among adults has not been
extensively studied. Previous reports pertaining to GBS risk factors
among non-pregnant adults have had various limitations such as:
(1) not enrolling controls, (2) not appropriately matching cases to
controls, (3) being underpowered to detect signiﬁcant differences
between controls and cases, and (4) not using SIRS-based
deﬁnitions to differentiate infection from colonization.12,17,21,26
Figure 1. The prevalence of group B Streptococcus isolations and rates of resistance
to second-line agents, Detroit Medical Center, 2005–2010.
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this study identiﬁed GBS as an opportunistic pathogen, acquired
mainly in the outpatient setting, in contrast to previous
reports;12,14 GBS was associated with complex and life-threaten-
ing clinical syndromes such as endocarditis and CNS infection,
i.e., particularly bacteremia cases. Other previously reported
GBS risk factors in adults, such as older age, diabetes, cardiovas-
cular diseases, alcoholism, and liver and renal insufﬁcien-
cy,3,4,9,12,14,17,26–29 were not signiﬁcant predictors in this study.
In order to be able to generalize these ﬁndings to other cohorts of
adult patients with GBS infection, a larger cohort of patients should
be analyzed following the same methodology and study design.
One interesting ﬁnding in this study was the unique indepen-
dent association between immunosuppression and invasive GBS
disease among adults. Immunosuppression has been reported as a
risk factor for GBS in multiple previous reports, but confounders
were not well controlled for.3,9–12,17,26,27 In neonates, the disease
commonly affects premature immunosuppressed newborns lack-
ing cellular immunity.30 In addition, several reports have
correlated low titers of anti-GBS maternal IgG antibodies with
the onset of neonatal disease, suggesting that humoral immunity
defects might also predispose to infection.31 Interestingly, both
neutropenia and glucocorticoid use, which result in severe
malfunction (although often transient) of two somewhat different
but overlapping immune response pathways, were associated with
all the cases of GBS disease in this cohort. Other more chronic
immunosuppressive conditions that were captured, such as
malignant comorbidity in general, recent chemotherapy or
radiotherapy, anti-tumor necrosis factor alpha (anti-TNF-a)
therapy, HIV or AIDS, and post-transplantation status, were not
signiﬁcantly associated with GBS infection.
Since GBS are susceptible to several commonly used anti-
microbials including penicillin and cephalosporins, patients with
GBS did not suffer from a delay in initiation of appropriate
antimicrobial therapy (DAAT) and overall had favorable outcomes
compared to matched controls. In univariate analysis, allergy to b-
lactams was signiﬁcantly associated with GBS disease. This is
particularly relevant in light of the high resistance rates to the
second-line agents (macrolides and clindamycin), which are used
only in patients allergic to b-lactam antibiotics. The resistance
rates are continually rising, both at DMC (Figure 1) and
worldwide.4,16,32–37 Close monitoring of the GBS susceptibility
proﬁle to antimicrobial agents is warranted.
The only outcomes that were unfavorable in the comparisons
between GBS cases and controls were hospital readmissions and
invasive procedures, although neither was signiﬁcantly associated
with GBS infection. GBS is a pathogen that even when treated
appropriately tends to recur. Nine (28%) of the patients in this
cohort experienced bacteriological failure despite prompt admin-istration of appropriate therapy. This is inconsistent with other
reports of much lower rates.5 However, this feature of GBS
infection has been reported in the past, particularly with wound
infections, and probably relates to the fact that the pathogen is not
fully eradicated and low inoculums persist in the gastrointestinal
tract.4,13 Treatment courses for serious GBS infection should
probably be prolonged, and validating bacteriological cure by
obtaining additional cultures appears warranted.
GBS bacteremias were frequently associated with CNS infec-
tions and with endocarditis. Three out of ﬁve BSI cases who
underwent diagnostic workup with echocardiography were
diagnosed with endocarditis. GBS should be considered for
inclusion in the future, at least as a minor criterion, in the
diagnostic Duke Criteria list of pathogens that are strongly
associated with endocarditis.38–41
To conclude, by using strict deﬁnitions and criteria for cases and
controls, this analysis has facilitated avoidance of possible
confounders like older age and diabetes and has determined the
unique independent role of immunosuppression on the occurrence
of GBS infections in adults. Despite the trend of reductions in
prevalence and incidence of GBS disease among adults at DMC (in
contrast to older reports from other locations),3,4 GBS infection is
strongly associated with severe clinical consequences. Continuing
efforts in vaccine development should also recognize and target
immunocompromised hosts, with all the complexities involved in
developing an effective vaccine for this population. As for neonates
and pregnant women, immunocompromised hosts could greatly
beneﬁt from the development of a new effective and safe measure
of prevention of GBS infection.
Conﬂict of interest: No potential conﬂicts of interest.
References
1. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, et al.
Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.
N Engl J Med 2000;342:15–20.
2. Centers for Disease Control and Prevention (CDC). Perinatal group B strepto-
coccal disease after universal screening recommendations—United States,
2003–2005. MMWR Morb Mortal Wkly Rep 2007;56:701–5.
3. Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin
Infect Dis 2005;41:839–47.
4. Farley MM. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis
2001;33:556–61.
5. Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, et al. Increasing
burden of invasive group B streptococcal disease in nonpregnant adults, 1990–
2007. Clin Infect Dis 2009;49:85–92.
6. Schuchat A. Epidemiology of group B streptococcal disease in the United States:
shifting paradigms. Clin Microbiol Rev 1998;11:497–513.
7. Baker CJ, Rench MA, Paoletti LC, Edwards MS. Dose–response to type V group B
streptococcal polysaccharide–tetanus toxoid conjugate vaccine in healthy
adults. Vaccine 2007;25:55–63.
8. Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease. Risk
factors, prevention strategies, and vaccine development. Epidemiol Rev
1994;16:374–402.
9. Lerner PI, Gopalakrishna KV, Wolinsky E, McHenry MC, Tan JS, Rosenthal M.
Group B Streptococcus (S. agalactiae) bacteremia in adults: analysis of 32 cases
and review of the literature. Medicine (Baltimore) 1977;56:457–73.
10. Farley MM, Harvey RC, Stull T, Smith JD, Schuchat A, Wenger JD, et al. A
population-based assessment of invasive disease due to group B Streptococcus
in nonpregnant adults. N Engl J Med 1993;328:1807–11.
11. Schwartz B, Schuchat A, Oxtoby MJ, Cochi SL, Hightower A, Broome CV. Invasive
group B streptococcal disease in adults. A population-based study in metropol-
itan Atlanta. JAMA 1991;266:1112–4.
12. Jackson LA, Hilsdon R, Farley MM, Harrison LH, Reingold AL, Plikaytis BD, et al.
Risk factors for group B streptococcal disease in adults. Ann Intern Med
1995;123:415–20.
13. Harrison LH, Ali A, Dwyer DM, Libonati JP, Reeves MW, Elliott JA, et al. Relapsing
invasive group B streptococcal infection in adults. Ann Intern Med
1995;123:421–7.
14. Verghese A, Mireault K, Arbeit RD. Group B streptococcal bacteremia in men.
Rev Infect Dis 1986;8:912–7.
15. Opal SM, Cross A, Palmer M, Almazan R. Group B streptococcal sepsis in adults
and infants. Contrasts and comparisons. Arch Intern Med 1988;148:641–5.
16. Munoz P, Llancaqueo A, Rodriguez-Creixems M, Pelaez T, Martin L, Bouza E.
Group B Streptococcus bacteremia in nonpregnant adults. Arch Intern Med
1997;157:213–6.
B. Sunkara et al. / International Journal of Infectious Diseases 16 (2012) e182–e186e18617. Trivalle C, Martin E, Martel P, Jacque B, Menard JF, Lemeland JF. Group B
streptococcal bacteraemia in the elderly. J Med Microbiol 1998;47:649–52.
18. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-
group selection importance in studies of antimicrobial resistance: examples
applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect
Dis 2002;34:1558–63.
19. Harris AD, Carmeli Y, Samore MH, Kaye KS, Perencevich E. Impact of severity of
illness bias and control group misclassiﬁcation bias in case–control studies of
antimicrobial-resistant organisms. Infect Control Hosp Epidemiol 2005;26:342–5.
20. Kaye KS, Harris AD, Samore M, Carmeli Y. The case–case–control study design:
addressing the limitations of risk factor studies for antimicrobial resistance.
Infect Control Hosp Epidemiol 2005;26:346–51.
21. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving
Sepsis Campaign: international guidelines for management of severe sepsis and
septic shock: 2008. Crit Care Med 2008;36:296–327.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation. J
Chronic Dis 1987;40:373–83.
23. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the
aged. The index of ADL: a standardized measure of biological and psychosocial
function. JAMA 1963;185:914–9.
24. Bion JF, Edlin SA, Ramsay G, McCabe S, Ledingham IM. Validation of a prognostic
score in critically ill patients undergoing transport. Br Med J (Clin Res Ed)
1985;291:432–4.
25. Clinical and Laboratory Standards Institute (CLSI). Performance standards for
antimibrobial susceptibility testing. Nineteenth informational supplement.
Approved standard M100-S19. Wayne, PA: CLSI; 2009.
26. Gallagher PG, Watanakunakorn C. Group B streptococcal bacteremia in a
community teaching hospital. Am J Med 1985;78:795–800.
27. Tyrrell GJ, Senzilet LD, Spika JS, Kertesz DA, Alagaratnam M, Lovgren M, et al.
Invasive disease due to group B streptococcal infection in adults: results from a
Canadian, population-based, active laboratory surveillance study—1996. Sen-
tinel Health Unit Surveillance System Site Coordinators. J Infect Dis
2000;182:168–73.
28. Eickhoff TC, Klein JO, Daly AK, Ingall D, Finland M. Neonatal sepsis and other
infections due to group B beta-hemolytic streptococci. N Engl J Med
1964;271:1221–8.
29. Bayer AS, Chow AW, Anthony BF, Guze LB. Serious infections in adults due to
group B streptococci. Clinical and serotypic characterization. Am J Med
1976;61:498–503.30. Baker CJ, Kasper DL. Immunological investigation of infants with septicemia or
meningitis due to group B Streptococcus. J Infect Dis 1977;136(Suppl):S98–104.
31. Baker CJ, Kasper DL. Correlation of maternal antibody deﬁciency with suscepti-
bility to neonatal group B streptococcal infection. N Engl J Med 1976;294:753–6.
32. Acikgoz ZC, Almayanlar E, Gamberzade S, Gocer S. Macrolide resistance deter-
minants of invasive and noninvasive group B streptococci in a Turkish hospital.
Antimicrob Agents Chemother 2004;48:1410–2.
33. Andrews JI, Diekema DJ, Hunter SK, Rhomberg PR, Pfaller MA, Jones RN, et al.
Group B streptococci causing neonatal bloodstream infection: antimicrobial
susceptibility and serotyping results from SENTRY centers in the Western
Hemisphere. Am J Obstet Gynecol 2000;183:859–62.
34. Baker CJ, Webb BJ, Barrett FF. Antimicrobial susceptibility of group B strepto-
cocci isolated from a variety of clinical sources. Antimicrob Agents Chemother
1976;10:128–31.
35. Borchardt SM, DeBusscher JH, Tallman PA, Manning SD, Marrs CF, Kurzynski TA,
et al. Frequency of antimicrobial resistance among invasive and colonizing
group B streptococcal isolates. BMC Infect Dis 2006;6:57.
36. De Azavedo JC, Yeung RH, Bast DJ, Duncan CL, Borgia SB, Low DE. Prevalence and
mechanisms of macrolide resistance in clinical isolates of group A streptococci
from Ontario, Canada. Antimicrob Agents Chemother 1999;43:2144–7.
37. Mehta S, McGeer A, Low DE, Hallett D, Bowman DJ, Grossman SL, et al.
Morbidity and mortality of patients with invasive group A streptococcal
infections admitted to the ICU. Chest 2006;130:1679–86.
38. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al.
Prevention of infective endocarditis: guidelines from the American Heart
Association: a guideline from the American Heart Association Rheumatic Fever,
Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular
Disease in the Young, and the Council on Clinical Cardiology, Council on
Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes
Research Interdisciplinary Working Group. Circulation 2007;116:1736–54.
39. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endo-
carditis: utilization of speciﬁc echocardiographic ﬁndings. Duke Endocarditis
Service. Am J Med 1994;96:200–9.
40. Duval X, Selton-Suty C, Alla F, Salvador-Mazenq M, Bernard Y, Weber M, et al.
Endocarditis in patients with a permanent pacemaker: a 1-year epidemiologi-
cal survey on infective endocarditis due to valvular and/or pacemaker infection.
Clin Infect Dis 2004;39:68–74.
41. Tleyjeh IM, Steckelberg JM, Murad HS, Anavekar NS, Ghomrawi HM, Mirzoyev Z,
et al. Temporal trends in infective endocarditis: a population-based study in
Olmsted County, Minnesota. JAMA 2005;293:3022–8.
